Related Experiment Video
Updated: Jul 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X
Puneet Kakar1, Timothy Watson, Gregory Y H Lip
1University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Abstract:
Bayer AG and Ortho-McNeil Pharmaceutical Inc are developing rivaroxaban, an oral Factor Xa inhibitor, for the potential prevention and treatment of thrombosis. In December 2005 and December 2006, phase III trials were initiated for the prevention of venous thromboembolism (VTE) following major orthopedic surgery and in patients with atrial fibrillation, respectively. By January 2007, a phase III trial for the prevention of VTE following total knee replacement surgery had commenced. In November 2006, a phase II trial for the reduction of VTE in patients with acute coronary syndrome was initiated.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Direct Renin Inhibitors
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care